JP2023175313A - Functional composition and functional display food product - Google Patents

Abstract

To provide use of fucose which provides basis of functionality in human beings and expands its application.SOLUTION: A functional composition for reducing and suppressing accumulation of subcutaneous fat or visceral fat contains fucose as an active ingredient. A functional composition for reducing and suppressing accumulation of abdominal fat contains fucose as an active ingredient. A composition for reducing and maintaining a waist surrounding size contains fucose as an active ingredient. A functional composition for reducing and maintaining a hip surrounding size contains a fucose as an active ingredient. A functional composition for reducing and maintaining BMI contains fucose as an active ingredient. A functional display food product contains fucose as a functionality-associated component, and displays supporting of reduction in BMI by assisting reduction in abdominal fat, a weight, and a waist surrounding diameter.SELECTED DRAWING: None

Description

There is an application for exception to loss of novelty.

The present invention relates to a functional composition containing fucose as an active ingredient, and a food with functional claims containing fucose as a functional ingredient.

Obesity is a chronic disease characterized by excessive fat accumulation in the body, and is considered a global public health issue (see Non-Patent Document 1). In Japan as well, among the approximately 29 million people who underwent specific health checkups in FY2018, the total number of people affected by metabolic syndrome and those who are at risk for metabolic syndrome is approximately 8.1 million (see Non-Patent Document 2). This chronic disease is thought to be deeply related to various diseases such as dyslipidemia, hyperuricemia, hypertension, and menstrual abnormalities (see Non-Patent Document 3), and Lifestyle interventions such as dietary guidance and supplement intake are becoming increasingly important.

On the other hand, fucose is a constituent sugar of the polysaccharide fucoidan, which is abundantly contained in brown algae. The present applicants have disclosed using fucose as an active ingredient for regulating adiponectin secretion (Patent Document 1). Furthermore, it has been reported that when mice were given fucose together with a high-calorie diet, increases in body weight and visceral fat were suppressed compared to a control group (Non-Patent Document 4).

Patent No. 6572496

NCD Risk Factor Collaboration “Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants” Lancet 2016; 387: 1377-96 Ministry of Health, Labor and Welfare “Details of the implementation status of specific health checkups and specific health guidance in 2019 (tally table)” Wataru Ogawa, Shigeru Miyazaki, “Diagnostic criteria for obesity and obesity,” Comprehensive Medical Examination 2015;42:59-64. Xiao Yuan, Tomohiko Nakao, Hina Satone, Kazuyuki Ohara, Yuri Kominami, Miho Ito, Teruki Aizawa, Tomoya Ueno and Hideki Ushio “The Effects of Brown Algae-Derived Monosaccharide L-Fucose on Lipid Metabolism in C57BL/6J Obese Mice” Nutrients 2020 , 12, 3798; doi:10.3390/nu12123798

Conventionally, regarding the use of fucose, although there have been reports on test animals such as mice, there is currently a lack of scientific knowledge that provides evidence of its functionality in humans.

Therefore, the purpose of the present invention is to provide evidence of the functionality of fucose in humans and to expand its range of applications.

The present invention has the following configuration.
[1] A functional composition for reducing and inhibiting accumulation of subcutaneous fat or visceral fat, containing fucose as an active ingredient.
[2] A functional composition for reducing and inhibiting accumulation of abdominal fat, containing fucose as an active ingredient.
[3] A functional composition for reducing and maintaining waist circumference, containing fucose as an active ingredient.
[4] A functional composition for reducing and maintaining hip circumference, containing fucose as an active ingredient.
[5] A functional composition for reducing and maintaining BMI, containing fucose as an active ingredient.
[6] The functional composition according to any one of [1] to [5] above, which is used so that more than 50 mg and less than 500 mg of fucose is ingested per day.
[7] The functional composition according to any one of [1] to [5] above, which is used in the form of a food or drink, a functional food, a medicine, or an animal feed.
[8] The functional composition according to any one of [1] to [5] above, which is used for subjects with a BMI of 23 or more and less than 30.
[9] A food with functional claims that contains fucose as a functional component and is labeled as supporting a reduction in BMI by helping to reduce abdominal fat, body weight, and waist circumference.
[10] The food with functional claims as described in [9] above, which further includes a label indicating that it improves bowel movements by increasing the frequency of stool for people who tend to be constipated.
[11] The food with functional claims according to [9] or [10] above, which is labeled as intended for people with a BMI of 23 or more and less than 30.

According to the present invention, fucose is used to reduce and suppress the accumulation of subcutaneous fat or visceral fat, to reduce and suppress the accumulation of abdominal fat, and to reduce and maintain waist circumference. It is possible to provide a composition with excellent functionality, such as the effect of reducing and maintaining hip circumference and the effect of reducing and maintaining BMI.

In Test Example 1, subjects ingested fucose-containing chewable tablets (test food) or placebo chewable tablets, and after a predetermined period of time, a physical examination was conducted. Figure 1a is a chart showing the results of abdominal visceral fat area. Figure 1b shows the results of abdominal subcutaneous fat area, Figure 1c shows the results of abdominal total fat area, Figure 1d shows the results of body weight, Figure 1e shows the results of BMI, and Figure 1f shows the results of waist circumference. Figure 1g shows the results for hip circumference. 2 is a chart showing the results of having subjects ingest fucose-containing chewable tablets (test food) or placebo chewable tablets and examining the state of defecation over a predetermined period in Test Example 1. In Test Example 2, subjects were asked to ingest fucose-containing chewable tablets (test food) or placebo chewable tablets, and a physical examination was conducted after a predetermined period of time. Figure 3a shows the results of abdominal visceral fat area. Figure 3b shows the hip circumference results.

The functional composition of the present invention contains fucose (also known as 6-deoxy-galactose) as an active ingredient. Here, enantiomers of fucose are known, but in the present invention, any of the L-form, D-form, a mixture thereof, and a racemate may be used. It is more preferable to use L-fucose, which is abundant in nature.

In the functional composition of the present invention, the content of fucose in the composition can be appropriately set from the viewpoint of the effective amount necessary to exhibit the desired functionality. The content of fucose in terms of dry matter can be, for example, 0.03% by mass or more and 100% by mass or less, 0.03% by mass or more and 90% by mass or less, and 0.03% by mass or more. 80% by mass or less, 0.03% by mass or more and 70% by mass or less, 0.03% by mass or more and 60% by mass or less, 0.03% by mass or more and 50% by mass % or less, 0.03% by mass or more and 40% by mass or less, 0.03% by mass or more and 30% by mass or less, 0.03% by mass or more and 20% by mass or less It can be 0.03% by mass or more and 10% by mass or less, and can be 0.03% by mass or more and 5% by mass or less. Further, when the functional composition of the present invention is in the form of a drink, the content of fucose in the composition can be, for example, 1 mg/100 mL or more and 1000 mg/100 mL or less, and 1 mg/100 mL or more. It can be 900 mg/100 mL or less, 1 mg/100 mL or more and 800 mg/100 mL or less, 1 mg/100 mL or more and 700 mg/100 mL or less, and 1 mg/100 mL or more and 600 mg/100 mL or less. 1 mg/100 mL or more and 500 mg/100 mL or less, 1 mg/100 mL or more and 400 mg/100 mL or less, 1 mg/100 mL or more and 300 mg/100 mL or less, and 1 mg/100 mL or more and 200 mg/100 mL or more It can be 100 mL or less, and can be 1 mg/100 mL or more and 100 mg/100 mL or less.

The functional composition of the present invention is not particularly limited in containing other components other than fucose, as long as the purpose is not impaired. Other ingredients other than fucose include, for example, excipients, disintegrants, binders, lubricants, coating agents, coloring agents, coloring agents, flavoring agents, flavoring agents, antioxidants, preservatives, and flavoring agents. agents, acidulants, sweeteners, fortifying agents, vitamins, swelling agents, thickeners, surfactants, and the like.

The form of use of the functional composition of the present invention is not particularly limited, but it is preferably used so as to be taken orally. In the case of an oral composition, fucose may be used as is, and if necessary, it may be in tablet form (tablet, tablet, chewable tablet, orally disintegrating agent), liquid form (liquid), It can be in the form of syrup, powder (granules, fine granules), capsule, soft capsule, solid, semi-liquid, cream, paste, etc. good.

By ingesting the functional composition of the present invention, its active ingredient, fucose, acts on the living body, resulting in effects such as reducing and inhibiting the accumulation of subcutaneous fat or visceral fat, and reducing and inhibiting the accumulation of abdominal fat. It is possible to exhibit excellent functionality, such as the effect of reducing and maintaining waist circumference, the effect of reducing and maintaining hip circumference, and the effect of reducing and maintaining BMI. Here, "reduction/suppression of accumulation" and "reduction/maintenance" mean that the values of each item do not increase beyond the desired level or are prevented from increasing compared to when the functional composition of the present invention is not ingested. The meaning also includes doing.

Further, according to the embodiments described later, in addition to the effects related to abdominal fat and body shape/physique exemplified above, it is also possible to obtain effects of improving bowel movement. Here, "improving bowel movements" specifically means that the number of defecations increases when averaged over a long period of time compared to when the functional composition of the present invention is not ingested, or conversely, it means that bowel movements become undesirable. The meaning also includes the prevention of.

The dosage of the functional composition of the present invention is not particularly limited and may be appropriately determined depending on the dosage form, the health condition or disease state of the human or animal to which it is applied, the purpose, etc. Fucose is a component that is also contained in human breast milk, and when typically administered orally, there is no particular problem in ingesting it in the range of 0.1 to 20,000 mg per adult per day in terms of fucose.

However, as shown in the examples below, in order to verify the functionality of fucose in humans, subjects were asked to ingest fucose-containing chewable tablets (test food) or placebo chewable tablets (control food) for a specified period of time. After verifying its effects on abdominal fat and bowel movements, we found that there is a preferable intake range for fucose in order to have the best effect on abdominal fat and body shape (hip circumference, etc.) It became clear that Therefore, from the results of the Examples, it is preferable that fucose be used so that more than 50 mg and less than 500 mg of fucose is ingested per day. The daily intake of fucose may be, for example, more than 50 mg and less than 400 mg, more than 60 mg and less than 300 mg, more than 60 mg and less than 250 mg, more than 70 mg and less than 200 mg, and more than 70 mg. It may be 150 mg or less. As for the period of ingestion, it is preferable that the drug is ingested for 4 weeks or more. The intake period is, for example, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks. This may be for weeks, 20 weeks, etc., and may be used to be taken over these periods.

Since fucose is orally ingested, the functional composition of the present invention may be in the form of, for example, a food or drink, a functional food, a pharmaceutical, an animal feed, or the like. Alternatively, it can also be used as a raw material for them.

Examples of food and drink products include (1) soft drinks, carbonated drinks, fruit drinks, vegetable juices, lactic acid bacteria drinks, milk drinks, soy milk, mineral water, tea drinks, coffee drinks, sports drinks, alcoholic drinks, jelly drinks, etc. Beverages, (2) Processed vegetable products such as tomato puree, canned mushrooms, dried vegetables, and pickles, (3) Processed fruit products such as dried fruit, jam, fruit puree, and canned fruit, (4) Curry powder, wasabi, and ginger. , spices such as spice blends and seasoning powder, (5) noodles (including fresh noodles and dried noodles) such as pasta, udon, soba, ramen, and macaroni; (6) breads such as white bread, sweet bread, cooked bread, and donuts; (7) Pregelatinized rice, oatmeal, wheat gluten, batter powder, etc., (8) Baked confectionery, biscuits, rice confectionery, candy, chocolate, chewing gum, snack confectionery, frozen confectionery, candied confectionery, Japanese confectionery, Western confectionery, semi-fresh confectionery, pudding. , confectionery such as ice cream, (9) Bean products such as azuki beans, tofu, natto, soybean flour, yuba, boiled beans, and peanuts, (10) Honey, processed royal jelly foods, (11) Meat products such as ham, sausage, bacon, etc. (12) Dairy products such as yogurt, pudding, condensed milk, cheese, fermented milk, butter, and ice cream, (13) Processed egg products, (14) Processed fish such as dried fish, kamaboko, chikuwa, and fish sausage, and dried seaweed. Processed seaweed such as kelp and tsukudani, processed fish eggs such as cod roe, herring roe, salmon roe, and karasumi (15) Dashi base, soy sauce, vinegar, mirin, consommé base, Chinese base, concentrated stock, dressing, mayonnaise, ketchup, Seasonings such as miso, edible oils and fats such as salad oil, sesame oil, linole oil, diacylglycerol, and safflower oil, (16) Cooked foods such as soup (including powder and liquid), semi-cooked foods, side dishes, retort foods, and chilled foods. , semi-cooked foods (for example, seasoned rice base, crab ball base), and the like.

Examples of functional foods include health foods, health drinks, supplements, nutritional supplements, foods with health claims, foods for specified health uses, foods with functional claims, food additive materials, and the like. The form of these products is not particularly limited. For example, similar to the above-mentioned forms, tablets (tablets, tablets, orally disintegrating agents), liquids (liquids), syrups (syrups), powders (granules, fine granules), capsules (capsules), soft capsules (soft capsule), solid, semi-liquid, cream, paste, etc.

The target animals for animal feed include pets such as dogs, cats, and birds, livestock such as cows, pigs, chickens, horses, sheep, and goats, and farmed fish such as tuna, yellowtail, eel, sea bream, and blowfish. etc. In this case, in addition to the other ingredients listed above, for example, flour, sugar, salt, fats and oils, vitamins, amino acids, polyphenols, nucleic acids, animal protein, vegetable protein, meat extract, fish extract, yeast extract, flavor Agents, pigments, lactic acid bacteria, antibiotics, hormones, etc. can be added.

On the other hand, another aspect of the present invention provides a food with functional claims that contains fucose as a functional component. Preferably, the signpost is a message such as ``Supports the reduction of BMI by helping to reduce abdominal fat, body weight, and waist circumference.'' Furthermore, as will be shown in the examples below, fucose has the effect of improving bowel movement, so the above label says, ``Improves bowel movement by increasing the frequency of bowel movement in people who tend to be constipated.'' You may also add an indication to that effect. Furthermore, in the verification of the functionality of fucose in humans as shown in the Examples below, we targeted people with a BMI of 23 or more and less than 30, so a statement such as "targeted on people with a BMI of 23 or more and less than 30" etc. may be added.

The fucose used in the present invention is not particularly limited, but from the viewpoint of being a material suitable for oral ingestion, it is preferable to use one prepared from natural raw materials. For example, by the method disclosed in WO 2018/180727 by the applicant, a hydrolyzate of a polysaccharide containing fucose, which is extracted from seaweeds such as Ascophyllum nodosum and Mozuku, as a constituent sugar, Since fucose can be efficiently prepared, it is preferable to use one prepared by such a method.

Below, the method for preparing fucose will be explained in more detail. However, the fucose used in the present invention is not limited to the preparation method exemplified below.

- Method for extracting polysaccharides containing fucose as part of the constituent sugars The raw material seaweed is preferably brown algae, with Ascophyllum nodosum and Okinawa Mozuku being particularly preferably used. A method for extracting polysaccharides containing fucose as part of the constituent sugars from raw material seaweed is to use an inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, or acetic acid, citric acid, lactic acid, oxalic acid, Add an aqueous solution of an organic acid such as malic acid, succinic acid, formic acid, propionic acid, etc. at a pH of 1 to 5 and a raw material concentration of 0.1 to 10% by weight as dry matter, and heat at 10 to 100°C to 0 to 24% by weight. An example is a method of extraction by stirring for a period of time. Preferably, hydrochloric acid is added to the raw material so that the pH is 2 to 5 and the concentration of the raw material is 3 to 8.5% by weight as dry matter, and the mixture is extracted at 70 to 90°C for 1 to 3 hours. More preferably, the raw material is pulverized using a mixer or the like before extraction.

- Method for removing low-molecular fractions from polysaccharides containing fucose as part of the constituent sugars After filtering the extract obtained by the above method, low-molecular substances such as mannitol are removed. There are no particular restrictions on the means or conditions, but for example, if the method is ultrafiltration according to a known method, the obtained extract can be directly applied to that method, and it is suitable for industrial use. It is preferable because it is suitable for mass production. More specifically, it is preferable that the means for molecular weight fractionation uses an ultrafiltration membrane that is capable of permeating at least mannitol. More specifically, the means for molecular weight fractionation preferably uses an ultrafiltration membrane with a molecular weight cutoff of 200 to 200,000; It is more preferable that it be used.

・Hydrolysis of polysaccharide containing fucose as a constituent sugar The polysaccharide containing fucose as a constituent sugar obtained as described above is used as a raw material and hydrolyzed. For example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as acetic acid, citric acid, oxalic acid, lactic acid, succinic acid, formic acid, and propionic acid, at a pH of 0.1 to 5, and dried extracts. An example of this method is to add it to a converted concentration of 0.1 to 25% by mass, and to hydrolyze it by stirring at 10 to 100°C for 0 to 24 hours. Preferably, hydrochloric acid is added to the extract so that the pH is 0.1 to 3 and the concentration of the extract in terms of dry matter is 3 to 6% by mass, and the mixture is stirred at 50 to 70°C for 1 to 5 hours for hydrolysis. do.

After the reaction is completed, the reaction solution is quickly cooled and neutralized to pH 7-8 with an alkaline agent such as sodium hydroxide or sodium carbonate. A fucose-containing hydrolyzate can be obtained by desalting this neutralized solution using activated carbon decolorization, filtration, an electrodialysis device, or the like.

- Fractionation and purification of fucose A fraction rich in fucose is separated and recovered from the above hydrolyzate. There are no particular restrictions on the means or conditions. For example, means using ultrafiltration, desalting, ion exchange, electrophoresis, molecular exclusion chromatography, molecular sieve, etc. according to known methods can be mentioned. Through this separation and recovery, impurities such as remaining alginic acid are removed and highly pure fucose is obtained. For example, it typically contains fucose in a dry matter concentration of 10% by mass or more, more typically contains 20% by mass or more, still more typically contains 30% by mass or more, particularly typically A fucose-containing composition containing 40% by mass or more can be obtained. Further, fucose can be highly purified by means such as crystallization, decoction, centrifugation, and chromatography separation according to known methods. This typically contains fucose in a dry matter concentration of 90% by weight or more, more typically 95% by weight or more, even more typically 98% by weight or more, particularly typically It is possible to obtain a fucose-containing composition containing 99% by mass or more.

In the present invention, when using a seaweed-derived composition as fucose, it is preferable to use a seaweed-derived composition containing 80% by mass or more of fucose based on dry matter, and a seaweed-derived composition containing 85% by mass or more of fucose based on dry matter is preferably used. It is more preferable to use a seaweed-derived composition containing 90% by mass or more, even more preferably to use a seaweed-derived composition containing 95% by mass or more. In this case, the content of sugars other than fucose in the seaweed-derived composition is preferably 0.001% by mass or more and 20% by mass or less, and 0.001% by mass or more and 15% by mass or less based on the dry matter. is more preferably 0.001% by mass or more and 10% by mass or less, even more preferably 0.001% by mass or more and 5% by mass or less, and 0.001% by mass or more and 3% by mass or less. Most preferably.

Note that the amount of fucose can be measured by, for example, high performance liquid chromatography (HPLC).

The present invention will be described in more detail below with reference to Examples, but these Examples do not limit the scope of the present invention.

[1. Test implementation system]
This study was conducted in accordance with the Declaration of Helsinki (revised in October 2013 at the WMA Fortareza General Assembly (Brazil)) and the Ethical Guidelines for Medical Research Involving Human Subjects (December 22, 2014, February 28, 2017). In accordance with the spirit of the Japanese Act (partially revised in Japan), we always paid attention to protecting the human rights of subjects, and after receiving approval from the Ethics Review Committee of Kimiokai Medical Corporation Kobuna Orthopedic Clinic, we registered the study contents in UMIN-CTR ( UMIN Exam ID: UMIN000038725). Written consent for research participation was received from all subjects, and the study was conducted under the supervision of doctors at the Shinagawa Season Terrace Health Checkup Clinic of the Seamen's Insurance Association and the Urayasu Sekiguchi Clinic of the Yukikai Medical Corporation.

[2. subject〕
Screening tests were conducted on the recruited volunteers based on pre-set selection criteria, or they were selected based on their wishes, and a predetermined number of volunteers were included in the study and assigned to two groups: a control food intake group and a test food intake group. . Specifically, the following [4. The survey targeted people with a Body Mass Index (BMI) of 23 or more and less than 30, and who were aware of poor stool quality such as chronic hard or soft stools. did. Also, see [5. Among all the subjects mentioned above, in particular, those who were prone to constipation (8 people in the control food group, 11 people in the test food group) had fewer than 6 defecations per week during the observation period before taking the test food. ).

[3. Sample food]
Chewable tablets each containing 150 mg of L-fucose were used as the test food. L-fucose was prepared by crystallizing edible brown algae (Ascophyllum nodosum) after acid hydrolysis, desalting, purification by an ion exchange method. The fucose purity was 99.6% as measured by high performance liquid chromatography. Chewable tablets containing no L-fucose were used as the control food. Table 1 summarizes the nutritional components of the prepared test food (chewable tablets). In addition, both chewable tablets are formulated to contain reduced maltose starch syrup, dextrin, cellulose, emulsifiers, and fragrances, and are designed so that they cannot be identified by flavor, texture, appearance, etc., and cannot be identified in advance before the start of the test. After confirming this, it was used for testing. In addition, the test subjects were asked to chew and ingest the test food (chewable tablets) in their mouths once a day for a predetermined period of time before a meal of their choice.

[4. Physical examination〕
A physical examination was conducted before the start of intake and after a predetermined period of time had passed since the start of intake. The physical examination items included weight, BMI, waist circumference, hip circumference, abdominal visceral fat area, abdominal subcutaneous fat area, and total abdominal fat area. Abdominal visceral fat area, abdominal subcutaneous fat area, and abdominal total fat area were evaluated by CT scan using conventional methods.

[5. Defecation status]
Subjects were asked to record their defecation status in a diary every day during the test period, and the number of defecation times per week was counted.

[6. Statistical analysis method]
Each data was analyzed using IBM SPSS Statistics 24 and shown as mean value ± standard deviation. Statistical analysis was performed using the Dunnett test (two-tailed test) to compare the test before the start of intake and the test after a predetermined period of time after the start of intake. In addition, a comparison between the control food intake group and the test food intake group at each test was statistically analyzed using an unpaired t-test (two-tailed test).

<Test Example 1>
In order to verify the functionality of fucose in humans, subjects were asked to ingest fucose-containing chewable tablets (test food) or placebo chewable tablets (control food) for 20 weeks, and the effects on abdominal fat and bowel movements were verified. (Test period: December 2019 to June 2020).

Specifically, a placebo-controlled, randomized, double-blind, parallel-group comparison study was conducted as follows. First, the person in charge of statistical analysis conducted a screening test and randomized the subjects into two groups using a stratified block randomization method using sex, age, body weight, and visceral fat area (VFA) as allocation adjustment factors. Next, the controller assigned the two groups to a control food intake group and a test food intake group, and created an assignment table. The allocation table was sealed in the controller and kept sealed until the allocation table was opened. During the study period, do not use medicines or health foods that may affect obesity, hyperlipidemia, lipid metabolism, etc., live the same life as before the study, and do not consume large amounts of alcohol. During the study period, you should not go to bed within 2 hours after dinner, do not eat meals including snacks after 10pm, wait at least 3 hours between meals, and avoid participating in other studies. This was explained to the subjects as precautions throughout the process. In addition, patients should not undergo an X-ray test that uses barium within one week before a CT scan, and should refrain from consuming raw fruits, raw vegetables, and carbonated drinks the day before a CT scan to prevent intestinal gas. Precautions for each test include avoiding alcohol consumption for two days before the test, avoiding eating or drinking anything other than water after 9:00 p.m. the day before the test, and refraining from smoking on the day of the test from the time you wake up until the end of the test. explained.

The results obtained for the physical examination items are shown in Tables 2 and 3 and Figure 1.

Furthermore, the results obtained regarding the defecation status are shown in Table 4 and FIG. 2.

As a result, regarding physical examination test items, as shown in Tables 2 and 3 and Figure 1, in the control food intake group, abdominal subcutaneous fat area and abdominal A significant increase in total fat area was observed. In a group comparison of actual measured values, the waist circumference at 4 and 20 weeks after the start of intake and the hip circumference at 4, 8 and 20 weeks after the start of intake were compared to the control food intake group, respectively. A significant decrease was observed in the group. In a group comparison of the amount of change, the abdominal visceral fat area of the test food intake group was observed at 20 weeks after the start of intake, and the abdominal subcutaneous fat area and total abdominal fat area were observed at 4, 8, and 20 weeks after the start of intake. , a significant decrease was observed compared to the control food intake group. In addition, a significant decrease in body weight of the test food intake group was observed at 4, 8, and 20 weeks after the start of intake compared to the control food intake group.

Regarding the defecation status, as shown in Table 4 and Figure 2, in the test food intake group, 5, 7, 8, 9, 10, 13, 14, 17, 18, 19, and 20 weeks after the start of intake, A significant increase in the frequency of defecation (times/week) was observed compared to before starting intake. On the other hand, no such tendency toward an increase in the frequency of defecation was observed in the control food intake group.

<Test Example 2>
A test similar to Test Example 1 was conducted by changing the content of fucose contained in one chewable tablet to 0 mg, 50 mg, 150 mg, and 500 mg (test period: January 2019 to May 2019).

The results obtained for the physical examination items are shown in Table 5 and FIG. 3.

As a result, as shown in Table 5 and Figure 3, only the test food intake group that ingested chewable tablets containing 150 mg of fucose per tablet had the effect of reducing abdominal visceral fat area and hip circumference. However, no such effect was observed in the test food intake group that ingested chewable tablets containing 50 mg of fucose per tablet or the test food intake group that ingested chewable tablets containing 500 mg of fucose per tablet. Ta.

Claims (11)

A functional composition for reducing and inhibiting accumulation of subcutaneous fat or visceral fat, containing fucose as an active ingredient. A functional composition for reducing and inhibiting the accumulation of abdominal fat, containing fucose as an active ingredient. A functional composition for reducing and maintaining waist circumference, containing fucose as an active ingredient. A functional composition for reducing and maintaining hip circumference, containing fucose as an active ingredient. A functional composition for reducing and maintaining BMI, containing fucose as an active ingredient. The functional composition according to any one of claims 1 to 5, wherein more than 50 mg and less than 500 mg of fucose is ingested per day. The functional composition according to any one of claims 1 to 5, which is used in the form of a food or drink, a functional food, a pharmaceutical, or an animal feed. The functional composition according to any one of claims 1 to 5, which is used for subjects with a BMI of 23 or more and less than 30. A food with functional claims that contains fucose as a functional component and is labeled as supporting a reduction in BMI by helping to reduce abdominal fat, body weight, and waist circumference. 10. The food with functional claims according to claim 9, further comprising a label indicating that the food improves bowel movements by increasing the frequency of defecation in people who tend to be constipated. 11. The food with functional claims according to claim 9 or 10, which is labeled as intended for people with a BMI of 23 or more and less than 30.